As part of its advocacy program in Europe, ACRO submits regulatory comments to European officials. This comment letter, submitted by ACRO to EMA in 2016 about Concept paper: Strategies to identify and mitigate risks for first-in-human clinical trials with investigational medicinal products can be found below.